This activity is expired and is no longer available for CME credit.


Moving Beyond the Basics in Ulcerative Colitis Treatment: Challenge Accepted - A Wheel of Knowledge Initiative

Author(s)/Faculty: William J. Sandborn, MD; Bruce E. Sands, MD, MS; Uma Mahadevan, MD
Release Date: 9/19/2016Expiration Date: 9/18/2017
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The American College of Gastroenterology (ACG) defined ulcerative colitis (UC) as “a chronic disease characterized by diffuse mucosal inflammation limited to the colon.” According to ACG practice guidelines, treatment for UC should induce and maintain remission of symptoms and mucosal inflammation to improve patients’ quality of life. Data from population-based cohort studies suggest that the clinical course of UC is good in many patients, but substantial room for improvement remains. Many patients experience frequent relapses alternating with therapeutically-induced and spontaneous periods of remission. The suboptimal outcomes that are common in patients with UC present substantial challenges to the physicians who treat them. This CME activity will differentiate available and emerging biomarkers, in addition to prognostic indicators used to determine disease severity, prognosis, and response to therapy. Mechanisms, safety profiles, efficacies, and indications for emerging and established therapeutic agents for mild-to-severe ulcerative colitis will be reviewed along with approaches for induction and maintenance treatment regimens.